Expeditors International of Wshngtn Inc vs Viatris Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $193.24 (market cap $25.18B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Expeditors International of Wshngtn Inc is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Viatris Inc for 57 Days on average.
| EXPD | VTRS | |
|---|---|---|
Market Cap | $25.18B | $20.03B |
Volume | 1,003,557 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $194.12 | $18.27 |
52-Week Low | $113.13 | $9.74 |
Typical Hold Time | 43 Days | 57 Days |
Enterprise Value | $24.72B | $32.15B |
Dividend Yield | 0.84% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $193.71, up 1.5% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement. Fundamentally, the company maintains solid profitability with 7.63% net margin and impressive 42.6% ROE, though revenue growth has moderated from 2022 peaks. Recent news highlights efficiency initiatives and dividend benefits driving positive sentiment.
The outlook remains cautiously optimistic with analyst consensus at $179.43 target, below current levels. Key opportunities include airfreight demand resilience and efficiency gains, while risks involve competitive pressures and potential margin compression. Institutional activity shows mixed signals with some major funds increasing positions while others reduced exposure in recent quarters.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →